NASDAQ:CRVO CervoMed Q2 2024 Earnings Report $2.79 -0.29 (-9.42%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$2.86 +0.08 (+2.69%) As of 08:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CervoMed EPS ResultsActual EPS-$0.27Consensus EPS -$0.24Beat/MissMissed by -$0.03One Year Ago EPSN/ACervoMed Revenue ResultsActual Revenue$3.29 millionExpected Revenue$3.48 millionBeat/MissMissed by -$190.00 thousandYoY Revenue GrowthN/ACervoMed Announcement DetailsQuarterQ2 2024Date8/12/2024TimeAfter Market ClosesConference Call DateMonday, August 12, 2024Conference Call Time4:00PM ETUpcoming EarningsCervoMed's Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CervoMed Earnings HeadlinesCervoMed (NASDAQ:CRVO) Receives "Buy" Rating from HC WainwrightJuly 16, 2026 | americanbankingnews.comCervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)July 14, 2026 | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.July 21 at 1:00 AM | Banyan Hill Publishing (Ad)FY2026 EPS Estimates for CervoMed Raised by HC WainwrightJuly 13, 2026 | americanbankingnews.comCervoMed Completes Enrollment in Phase 2a Neflamapimod TrialJuly 9, 2026 | tipranks.comCervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal DementiaJuly 9, 2026 | globenewswire.comSee More CervoMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email. Email Address About CervoMedCervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.View CervoMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
